ArticleHealth science reports2025
Assessment of
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Significance of Tumor Invasion Gene Profiling in Early-Stage Hormone Receptor-Positive Breast Cancer: A Cross-Sectional Study.Health science reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Hormone receptors are expressed in 70% of breast cancers and are the major biomarkers for tailoring treatment in early-stage breast cancer. In clinical routine, immunohistochemistry (IHC) is used to assess estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki67 protein expression. However, IHC procedure is challenged with pre-analytical and analytical variability. Pathologist interpretation of IHC results can vary, and discordant results between local and reference laboratories have been reported. Using mRNA-based tests may be a more robust, reliable, and standardized method to assess these important breast cancer biomarkers. This study aimed to assess the concordance between real-time PCR and IHC results. Methods: In this study, we analyzed 178 early-stage hormone receptor-positive breast tumors. IHC for ER, PR, HER2, and Ki67 had been previously performed for the study samples at local laboratories. For samples with HER2 IHC score 2+, Fluorescence In Situ Hybridization was performed. Results: The overall concordance between mRNA expression results and their corresponding IHC markers was 95.9% for Conclusions: PCR-based classification of breast tumors in a central laboratory may be used to confirm the available IHC results performed at local laboratories and add valuable information for patient management. mRNA-based biomarkers may be promising for more standardized breast cancer management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.